Comparative Pharmacology
Head-to-head clinical analysis: NORCURON versus ROCURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORCURON versus ROCURONIUM BROMIDE.
NORCURON vs ROCURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and inducing skeletal muscle paralysis.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking acetylcholine binding and inhibiting muscle contraction.
0.08-0.1 mg/kg IV bolus for intubation; maintenance 0.01-0.015 mg/kg IV every 30-60 min as needed or continuous infusion at 0.06-0.12 mg/kg/hr.
0.6 mg/kg IV bolus for intubation; maintenance: 0.1-0.2 mg/kg IV bolus as needed or continuous infusion 5-10 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3-2.2 hours in adults; prolonged in hepatic or renal impairment (up to 3-4 hours in renal failure).
Terminal elimination half-life: 1.4-2.4 minutes (distribution half-life: 3-5 minutes); recovery index (25-75%): 12-16 minutes; clinical duration (dose-dependent): 30-45 minutes (0.6 mg/kg) to 70-90 minutes (1.2 mg/kg)
Approximately 40-50% of the dose is excreted unchanged in urine within 24 hours; 20-30% is eliminated in feces as unchanged drug and metabolites; minor biliary excretion.
Renal: 33% unchanged; Biliary/fecal: 33% (as parent and metabolite); Hepatic metabolism: ~10-20%; remainder: unknown
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker